Literature DB >> 11238522

A prion-like shift between two conformational forms of a recombinant thyrotropin receptor A-subunit module: purification and stabilization using chemical chaperones of the form reactive with Graves' autoantibodies.

G D Chazenbalk1, S M McLachlan, P Pichurin, X M Yan, B Rapoport.   

Abstract

A secreted recombinant TSH receptor (TSHR) ectodomain variant (TSHR-289) neutralizes TSHR autoantibodies in Graves' disease, but is heterogeneous in containing both immunologically active and inactive molecules and is also unstable. We have now purified each form of TSHR-289 using sequential affinity chromatography with a mouse mAb (3BD10) specific for the inactive form, and a mAb to C-terminal His residues that recognizes both forms. The immunological difference between active and inactive TSHR-289 was unrelated to primary amino acid sequence or carbohydrate content and was, therefore, attributable to its folded state. The epitopes for Graves' autoantibodies and 3BD10 overlap, and both are destroyed by denaturation. Therefore, reciprocal binding by autoantibodies and 3BD10 to conformational determinants involving the same TSHR segment suggests a prion-like shift between two folded states of the molecule. Despite purification, immunologically active TSHR-289 remained labile, as determined by loss of autoantibody, and gain of 3BD10, recognition. However, using chemical chaperones we have, for the first time, been able to stabilize purified TSHR antigen in immunologically intact form. In summary, purification of immunologically active and stable antigen in milligram quantities provides a powerful tool for future diagnostic and therapeutic studies in Graves' disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238522     DOI: 10.1210/jcem.86.3.7363

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  20 in total

1.  Insight into thyroid-stimulating autoantibody interaction with the thyrotropin receptor N-terminus based on mutagenesis and re-evaluation of ambiguity in this region of the receptor crystal structure.

Authors:  Sepehr Hamidi; Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  Thyroid       Date:  2011-08-11       Impact factor: 6.568

2.  Studies in mice deficient for the autoimmune regulator (Aire) and transgenic for the thyrotropin receptor reveal a role for Aire in tolerance for thyroid autoantigens.

Authors:  Alexander V Misharin; Yuji Nagayama; Holly A Aliesky; Basil Rapoport; Sandra M McLachlan
Journal:  Endocrinology       Date:  2009-03-05       Impact factor: 4.736

3.  Structure of a Thyrotropin Receptor Monoclonal Antibody Variable Region Provides Insight into Potential Mechanisms for its Inverse Agonist Activity.

Authors:  Chun-Rong Chen; Sandra M McLachlan; Paul A Hubbard; Randall McNally; Ramachandran Murali; Basil Rapoport
Journal:  Thyroid       Date:  2018-06-29       Impact factor: 6.568

4.  Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors.

Authors:  S Costagliola; V Panneels; M Bonomi; J Koch; M C Many; G Smits; G Vassart
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

5.  Nanoparticles Bearing TSH Receptor Protein and a Tolerogenic Molecule Do Not Induce Immune Tolerance but Exacerbate Thyroid Autoimmunity in hTSHR/NOD.H2h4 Mice.

Authors:  Sandra M McLachlan; Holly A Aliesky; Basil Rapoport
Journal:  J Immunol       Date:  2019-04-03       Impact factor: 5.422

6.  Adenovirus-mediated gene delivery of interleukin-10, but not transforming growth factor beta, ameliorates the induction of Graves' hyperthyroidism in BALB/c mice.

Authors:  O Saitoh; Y Mizutori; N Takamura; H Yamasaki; A Kita; H Kuwahara; Y Nagayama
Journal:  Clin Exp Immunol       Date:  2005-09       Impact factor: 4.330

7.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 8.  Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity.

Authors:  Sandra M McLachlan; Basil Rapoport
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

9.  Evidence that factors other than particular thyrotropin receptor T cell epitopes contribute to the development of hyperthyroidism in murine Graves' disease.

Authors:  P N Pichurin; Chun-Rong Chen; Y Nagayama; O Pichurina; B Rapoport; S M McLachlan
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

10.  Attenuation of induced hyperthyroidism in mice by pretreatment with thyrotropin receptor protein: deviation of thyroid-stimulating to nonfunctional antibodies.

Authors:  Alexander V Misharin; Yuji Nagayama; Holly A Aliesky; Yumiko Mizutori; Basil Rapoport; Sandra M McLachlan
Journal:  Endocrinology       Date:  2009-04-23       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.